Pulmonx (LUNG) Set to Announce Earnings on Wednesday

Pulmonx (NASDAQ:LUNG) will post its quarterly earnings results after the market closes on Wednesday, July 31st. Analysts expect Pulmonx to post earnings of ($0.41) per share for the quarter. Pulmonx has set its FY 2024 guidance at EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings results on Wednesday, May 1st. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.07. Pulmonx had a negative net margin of 80.46% and a negative return on equity of 48.09%. The company had revenue of $18.85 million for the quarter, compared to analysts’ expectations of $17.54 million. During the same quarter in the previous year, the company earned ($0.42) earnings per share. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Pulmonx Stock Performance

Shares of LUNG opened at $7.04 on Tuesday. Pulmonx has a one year low of $5.67 and a one year high of $14.84. The company has a 50-day simple moving average of $7.05 and a two-hundred day simple moving average of $9.18. The company has a debt-to-equity ratio of 0.29, a current ratio of 6.95 and a quick ratio of 6.14. The firm has a market capitalization of $273.29 million, a PE ratio of -4.57 and a beta of 0.62.

Insider Transactions at Pulmonx

In other Pulmonx news, insider Geoffrey Beran Rose sold 4,297 shares of Pulmonx stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $6.97, for a total value of $29,950.09. Following the completion of the sale, the insider now owns 301,203 shares of the company’s stock, valued at approximately $2,099,384.91. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, General Counsel David Aaron Lehman sold 5,475 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $6.97, for a total value of $38,160.75. Following the completion of the transaction, the general counsel now owns 209,113 shares of the company’s stock, valued at $1,457,517.61. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Geoffrey Beran Rose sold 4,297 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $6.97, for a total value of $29,950.09. Following the sale, the insider now owns 301,203 shares of the company’s stock, valued at approximately $2,099,384.91. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,140 shares of company stock worth $85,717. Corporate insiders own 5.70% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Lake Street Capital began coverage on Pulmonx in a research note on Tuesday, June 4th. They issued a “buy” rating and a $12.00 price target on the stock. Canaccord Genuity Group reduced their target price on shares of Pulmonx from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, May 2nd. Finally, Piper Sandler reissued an “overweight” rating and set a $17.00 price target on shares of Pulmonx in a research report on Wednesday, April 3rd. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Pulmonx presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.71.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.